Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) Director Daniel P. Getman sold 20,000 shares of the stock in a transaction that occurred on Tuesday, November 29th. The stock was sold at an average price of $16.86, for a total value of $337,200.00. Following the completion of the transaction, the director now owns 16,201 shares of the company’s stock, valued at $273,148.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) traded down 5.25% during mid-day trading on Wednesday, reaching $16.25. The company’s stock had a trading volume of 809,920 shares. The stock has a market capitalization of $695.79 million, a P/E ratio of 54.90 and a beta of 1.62. The stock’s 50 day moving average price is $13.49 and its 200 day moving average price is $12.15. Sucampo Pharmaceuticals Inc. has a 1-year low of $9.59 and a 1-year high of $18.75.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.02. The company earned $57.90 million during the quarter, compared to the consensus estimate of $51.30 million. Sucampo Pharmaceuticals had a return on equity of 44.19% and a net margin of 6.29%. Sucampo Pharmaceuticals’s revenue was up 73.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.16 EPS. Analysts expect that Sucampo Pharmaceuticals Inc. will post $1.22 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Sucampo Pharmaceuticals Inc. (SCMP) Director Sells $337,200.00 in Stock” was posted by Financial Market News and is the propert of of Financial Market News. If you are accessing this article on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The original version of this article can be read at http://www.financial-market-news.com/sucampo-pharmaceuticals-inc-scmp-director-sells-337200-00-in-stock/1211193/.

Several research analysts recently weighed in on SCMP shares. Maxim Group increased their price objective on Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, November 15th. Vetr lowered Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price target for the company. in a research report on Monday, September 19th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Jefferies Group lowered their price target on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating for the company in a research report on Thursday, August 4th. Finally, Mizuho raised their price target on Sucampo Pharmaceuticals from $13.00 to $16.00 and gave the stock a “neutral” rating in a research report on Monday, November 14th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Sucampo Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $17.33.

A number of hedge funds and other institutional investors have recently modified their holdings of SCMP. Globeflex Capital L P increased its stake in Sucampo Pharmaceuticals by 0.3% in the second quarter. Globeflex Capital L P now owns 23,649 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 61 shares during the last quarter. Smith Asset Management Group LP increased its stake in Sucampo Pharmaceuticals by 2.1% in the third quarter. Smith Asset Management Group LP now owns 10,950 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 220 shares during the last quarter. ProShare Advisors LLC increased its stake in Sucampo Pharmaceuticals by 1.0% in the second quarter. ProShare Advisors LLC now owns 36,954 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 369 shares during the last quarter. BlackRock Group LTD increased its stake in Sucampo Pharmaceuticals by 2.0% in the third quarter. BlackRock Group LTD now owns 20,706 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 405 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Sucampo Pharmaceuticals by 1.6% in the third quarter. Rhumbline Advisers now owns 27,355 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 425 shares during the last quarter. Institutional investors own 41.12% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.